{"ctNumber":"2023-504439-42-03","ctStatus":"Authorised","decisionDate":"2026-06-08T09:27:46.715","publishDate":"2026-06-09T03:39:14.422361113","ctPublicStatusCode":2,"authorizedApplication":{"authorizedPartI":{"id":128814,"rowSubjectCount":0,"products":[{"id":535251,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPharmForm":"N/A","euMpNumber":"N/A","marketingAuthNumber":"N/A","prodName":"Placebo to cannabidiol","pharmForm":"N/A","activeSubstanceName":"N/A","euSubstNumber":"N/A","productOtherName":"N/A","authorisationCountryCode":"IS","nameOrg":"N/A","sponsorSubstanceCode":"N/A","atcCode":"N/A","atcName":"N/A","atcTermLevel":"N/A","activeSubstanceOtherDescriptiveName":"N/A"},"isPaediatricFormulation":false,"mpRoleInTrial":"3","timeUnitCode":"2","evCode":"N/A","devices":[],"characteristics":[],"routes":[],"allSubstancesChemicals":false,"productName":"Placebo to cannabidiol","jsonActiveSubstanceNames":"n/a","pharmaceuticalFormDisplay":"N/A"},{"id":535252,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11344601","productPharmForm":"ORAL SOLUTION","euMpNumber":"PRD11344601","prodAuthStatus":1,"prodName":"Cannabidiol","pharmForm":"ORAL SOLUTION","sponsorProductCode":" Cannabidiol","activeSubstanceName":"CANNABINOL","euSubstNumber":"SUB06074MIG","nameOrg":"START FROM SCRATCH S.L.","productSubstances":[{"productPk":"11344601","substancePk":"331883","nameOrg":"START FROM SCRATCH S.L.","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"CANNABINOL","substanceEvCode":"SUB06074MIG"}],"atcCode":"N03AX24","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"600","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"33600","maxTreatmentPeriod":8,"timeUnitCode":"2","evCode":"PRD11344601","sponsorProductCodeEdit":" Cannabidiol","devices":[],"characteristics":["2","1"],"routes":["ORAL USE"],"allSubstancesChemicals":true,"productName":"Cannabidiol","jsonActiveSubstanceNames":"cannabinol","pharmaceuticalFormDisplay":"ORAL SOLUTION"}],"trialDetails":{"clinicalTrialIdentifiers":{"fullTitle":"Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)","fullTitleTranslations":[{"id":10725487,"uuid":"0156db08-0a02-45ff-980e-2a1dce2aff40","attributeTranslation":"Ensayo Fase II de Cannabidiol, controlado por placebo, para el tratamiento de la dependencia del alcohol.","language":7,"languageDescription":"Spanish"}],"publicTitle":"Trial of Cannabidiol for the treatment of alcohol dependence","publicTitleTranslations":[{"id":10725497,"uuid":"9b98b0c0-811c-4a8b-b78e-b93e39258947","attributeTranslation":"Ensayo de Cannabidiol para el tratamiento de la dependencia del alcohol.","language":7,"languageDescription":"Spanish"}],"shortTitle":"PLACONCANALDE","secondaryIdentifyingNumbers":{"additionalRegistries":[]}},"trialInformation":{"trialCategory":{"isLowIntervention":false,"trialPhase":"4","trialCategory":"2","justificationForTrialCategory":"Phase II trial","trialCategoryId":118474},"medicalCondition":{"partIMedicalConditions":[{"id":134357,"medicalCondition":"alcohol dependence","medicalConditionTranslations":[{"id":10725467,"uuid":"5a632d1e-8373-4763-bece-1833de7be12c","attributeTranslation":"Alcoholismo","language":7,"languageDescription":"Spanish"}],"isConditionRareDisease":false}],"meddraConditionTerms":[{"termId":100000035046,"version":"21.0","level":"LLT","termName":"Alcohol abuse chronic","classificationCode":"10001585","organClass":10037175,"active":false}]},"trialObjective":{"trialScopes":[{"code":"3","trialScopeId":390684}],"mainObjective":"Determine the change in the Timeline Follow-back (TLFB) assessment of alcohol consumption and the change in percent Carbohydrate Deficient Transferrin (CDT) in serum, to evaluate the therapeutic potential of CBD in the management of patients with alcohol dependence who are seeking treatment to achieve abstinence.","mainObjectiveTranslations":[{"id":10725496,"uuid":"9b1eb85e-60b0-4779-b58c-da4a7dd2a33a","attributeTranslation":"Determinar el cambio en el cuestionario “Timeline Follow-Back” (TLFB) de evaluación del consumo de alcohol y en el porcentaje de la Transferrina deficiente en carbohidrato (CDT) en suero, para evaluar el potencial terapéutico de CBD en el manejo de pacientes con dependencia del alcohol que buscan un tratamiento para obtener abstinencia.","language":7,"languageDescription":"Spanish"}],"secondaryObjectives":[{"id":456732,"number":1,"secondaryObjective":"Evaluate the effect of CBD on selfrepots of anxiety, depression, impulsivity, and alcohol craving.","secondaryObjectiveTranslations":[{"id":10725498,"uuid":"adba4cb7-155d-44d4-bc99-e9161940dbe6","attributeTranslation":"Evaluar el efecto de CBD en autoinformes de ansiedad, depresión, impulsividad y deseo o craving por alcohol.","language":7,"languageDescription":"Spanish"}]},{"id":456733,"number":2,"secondaryObjective":"Confirm tolerability and safety of CBD in these patients under the dose and pattern of administration.","secondaryObjectiveTranslations":[{"id":10725499,"uuid":"88972514-4de8-458e-bd1a-bfff07bf7c53","attributeTranslation":"Confirmar la tolerabilidad y seguridad de CBD en estos pacientes según la dosis y el patrón de administración","language":7,"languageDescription":"Spanish"}]},{"id":456734,"number":3,"secondaryObjective":"Determine modifications in gene expression in peripheral blood mononuclear cells (PBMCs), and endocannabinoids in plasma to identify biomarkers associated to the clinical changes induced by CBD.","secondaryObjectiveTranslations":[{"id":10725500,"uuid":"d415907d-0af9-4a04-8ccb-21a330f29806","attributeTranslation":"Determinar modificaciones en la expresión de genes en células periféricas mononucleares (PBMCs) y endocannabinoides en plasma para identificar biomarcadores asociados a los cambios clínicos inducidos por CBD.","language":7,"languageDescription":"Spanish"}]}]},"eligibilityCriteria":{"principalInclusionCriteria":[{"id":871202,"number":1,"principalInclusionCriteria":"Males and females aged 18-65","principalInclusionCriteriaTranslations":[{"id":10725488,"uuid":"38e99423-74ed-4b7e-947e-0b6315472eae","attributeTranslation":"Hombres y mujeres entre 18 y 65 años","language":7,"languageDescription":"Spanish"}]},{"id":871203,"number":2,"principalInclusionCriteria":"DSM-5 diagnosis of moderate or severe AUD.","principalInclusionCriteriaTranslations":[{"id":10725489,"uuid":"0fb15120-f355-49a5-a9ca-ac765265d74f","attributeTranslation":"Diagnóstico DSM 5 de trastorno por uso de alcohol (TUA) moderado o severo","language":7,"languageDescription":"Spanish"}]},{"id":871204,"number":3,"principalInclusionCriteria":"Able to provide voluntary informed consent.","principalInclusionCriteriaTranslations":[{"id":10725490,"uuid":"2da78c26-85df-44e6-b22c-dafe4a183e3c","attributeTranslation":"Capacidad para firmar un consentimiento informado de forma voluntaria","language":7,"languageDescription":"Spanish"}]},{"id":871205,"number":4,"principalInclusionCriteria":"At least 8 heavy drinking days (4 or more drinks for a woman, 5 or more drinks for a man) in the 30 days prior to screen.","principalInclusionCriteriaTranslations":[{"id":10725491,"uuid":"aab67c02-9b90-4d4b-b46c-61bf42b5081e","attributeTranslation":"Un consumo previo de alcohol de al menos 8 días de toma intensa (4 o más bebidas para mujeres y 5 o más bebidas para hombres) en los últimos 30 días previos a la evaluación.","language":7,"languageDescription":"Spanish"}]},{"id":871206,"number":5,"principalInclusionCriteria":"If of childbearing potential (male or female), are willing to use approved form of contraception from screening for duration of the trial.","principalInclusionCriteriaTranslations":[{"id":10725492,"uuid":"ee6608a7-a2be-4562-a1a1-fc25cd6bb0d5","attributeTranslation":"En caso de estar en edad fértil (hombre o mujer), si están dispuestos a utilizar un método anticonceptivo aprobado, desde el comienzo de la evaluación hasta la finalización del ensayo","language":7,"languageDescription":"Spanish"}]},{"id":871207,"number":6,"principalInclusionCriteria":"Able to provide at least two locators.","principalInclusionCriteriaTranslations":[{"id":10725493,"uuid":"f67ccaaa-90f2-470b-a1e7-45e23b7f0458","attributeTranslation":"Ser capaz de proporcionar al menos dos localizadores","language":7,"languageDescription":"Spanish"}]},{"id":871208,"number":7,"principalInclusionCriteria":"Endorse desire to cut down or stop drinking.","principalInclusionCriteriaTranslations":[{"id":10725494,"uuid":"4caf4f81-e847-4e03-925d-c7848449844d","attributeTranslation":"Afirmar de forma explícita el deseo de reducir o dejar de consumir alcohol","language":7,"languageDescription":"Spanish"}]},{"id":871209,"number":8,"principalInclusionCriteria":"Endorse desire to cut down or stop drinking.","principalInclusionCriteriaTranslations":[{"id":10725495,"uuid":"5b29359a-07e0-4849-87b7-dc6994e203cf","attributeTranslation":"Acepta abstenerse de consumir cualquier otro cannabinoide mientras dure el estudio","language":7,"languageDescription":"Spanish"}]}],"principalExclusionCriteria":[{"id":1489853,"number":1,"principalExclusionCriteria":"Current alcohol withdrawal (CIWA-Ar score >7).","principalExclusionCriteriaTranslations":[{"id":10725472,"uuid":"71698051-7b95-47fd-8103-d0951c41beb6","attributeTranslation":"Abstinencia alcohólica actual (puntuación CIWA-Ar >7).","language":7,"languageDescription":"Spanish"}]},{"id":1489854,"number":10,"principalExclusionCriteria":"Pregnancy or lactation.","principalExclusionCriteriaTranslations":[{"id":10725473,"uuid":"5e671e70-ca00-4334-93a1-fdda05e13a02","attributeTranslation":"Embarazo o lactancia","language":7,"languageDescription":"Spanish"}]},{"id":1489855,"number":11,"principalExclusionCriteria":"Current use of exclusionary medications, including cannabinoids; treatments for addictions including alcohol; moderate to strong inhibitors of CYP3A4 or CYP2C19; medications metabolized primarily by CYP3A4, CYP3A5, or CYP3A7; and medications with a narrow therapeutic index which are substrates of UGT1A9, UGT2B7, CYP2C8, CYP2C9, CYP2C19, CYP1A2, or CYP2B6.","principalExclusionCriteriaTranslations":[{"id":10725474,"uuid":"7c2f06ff-c1ad-45a3-8c98-124a3d3a6df1","attributeTranslation":"Uso actual de medicamentos excluyentes, incluidos los cannabinoides; tratamientos para adicciones, incluido el alcohol; inhibidores moderados de CYP3A4 o CYP2C19; medicamentos metabolizados sobre todo por CYP3A4, CYP3A5, o CYP3A7; y medicamentos con un índice terapéutico estrecho que son substratos de UGT1A9, UGT2B7, CYP2C8, CYP2C9, CYP2C19, CYP1A2, o CYP2B6","language":7,"languageDescription":"Spanish"}]},{"id":1489856,"number":12,"principalExclusionCriteria":"Allergy to any ingredient of the study compound.","principalExclusionCriteriaTranslations":[{"id":10725475,"uuid":"fbbf889a-0bc1-4e9b-b1b8-63f7acb140c6","attributeTranslation":"Alergia a cualquier ingrediente del compuesto del estudio.","language":7,"languageDescription":"Spanish"}]},{"id":1489857,"number":13,"principalExclusionCriteria":"Current treatment for AUD, with exception of AA/12-step treatment/mutual-help groups-.","principalExclusionCriteriaTranslations":[{"id":10725476,"uuid":"e5807a8a-7fab-48c6-905c-bede4d98ca06","attributeTranslation":"Tratamiento actual para el alcoholismo y la adicción, con la excepción de tratamiento de 12 pasos de AA/grupos de ayuda mutua.","language":7,"languageDescription":"Spanish"}]},{"id":1489858,"number":14,"principalExclusionCriteria":"No inpatient psychiatric treatment in the last 12 months, with the exception of detox and extended Emergency Department stays.","principalExclusionCriteriaTranslations":[{"id":10725477,"uuid":"d69574b3-64cb-4af0-ab97-486f22e374d8","attributeTranslation":"Ningún tratamiento psiquiátrico hospitalario en los últimos 12 meses, a excepción de desintoxicación y estancias prolongadas en el Servicio de Urgencias.","language":7,"languageDescription":"Spanish"}]},{"id":1489859,"number":15,"principalExclusionCriteria":"A positive urine drug screen for THC, cocaine and/or opioids at screen.","principalExclusionCriteriaTranslations":[{"id":10725478,"uuid":"decc2335-d5ce-44ac-917f-80079da8d3b9","attributeTranslation":"Un análisis de orina positivo para THC, cocaína y/u opiáceos en el momento del cribado.","language":7,"languageDescription":"Spanish"}]},{"id":1489860,"number":2,"principalExclusionCriteria":"Exclusionary medical conditions (e.g., current severe alcohol withdrawal requiring medical hospitalization, significantly impaired liver function).","principalExclusionCriteriaTranslations":[{"id":10725479,"uuid":"c64b6ebd-b849-437e-9ca7-cb8a2a866950","attributeTranslation":"Afecciones médicas excluyentes (p. ej., síndrome de abstinencia alcohólica grave actual que requiera hospitalización médica, función hepática significativamente alterada).","language":7,"languageDescription":"Spanish"}]},{"id":1489861,"number":3,"principalExclusionCriteria":"DSM-5 diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder.","principalExclusionCriteriaTranslations":[{"id":10725480,"uuid":"5c6be9cb-5dde-495b-9b08-285d647575ec","attributeTranslation":"Diagnóstico DSM-5 de esquizofrenia, trastorno esquizoafectivo, trastorno bipolar.","language":7,"languageDescription":"Spanish"}]},{"id":1489862,"number":4,"principalExclusionCriteria":"High risk of adverse emotional or behavioral reaction based on investigator's clinical evaluation (e.g., evidence of serious personality disorder, antisocial behavior, serious current stressors, lack of meaningful social support).","principalExclusionCriteriaTranslations":[{"id":10725481,"uuid":"a333ac9f-4eba-4a46-a24d-15d871ae49bf","attributeTranslation":"Alto riesgo de reacción emocional o conductual adversa según la evaluación clínica del investigador (p. ej., evidencia de trastorno grave de la personalidad, conducta antisocial, factores estresantes actuales graves, falta de apoyo social significativo).","language":7,"languageDescription":"Spanish"}]},{"id":1489863,"number":5,"principalExclusionCriteria":"Current significant suicidality (assessed using the C-SSRS), any suicidal behavior in the past 12 months, or any history of serious suicide attempts requiring hospitalization, or current significant homicidally.","principalExclusionCriteriaTranslations":[{"id":10725482,"uuid":"ba1e2d9d-72da-43b6-8a37-368a9288d02c","attributeTranslation":"Riesgo de suicidio significativo actual (evaluado mediante la C-SSRS), cualquier comportamiento suicida en los últimos 12 meses, o cualquier historial de intentos de suicidio graves que hayan requerido hospitalización, o riesgo de homicidio significativo actual.","language":7,"languageDescription":"Spanish"}]},{"id":1489864,"number":6,"principalExclusionCriteria":"History of severe Traumatic Brain Injury (LOC > 24 hours).","principalExclusionCriteriaTranslations":[{"id":10725483,"uuid":"058be7bd-c7d6-4e91-9bb5-32ae8906c5f6","attributeTranslation":"Antecedentes de lesión cerebral traumática grave (LOC > 24 horas).","language":7,"languageDescription":"Spanish"}]},{"id":1489865,"number":7,"principalExclusionCriteria":"DSM-5 diagnosis of current mild cannabis use disorder and/or moderate or severe substance use disorder for a substance other than alcohol or nicotine.","principalExclusionCriteriaTranslations":[{"id":10725484,"uuid":"fa5763f4-72db-4999-ada2-0ca9c90b5fa9","attributeTranslation":"Diagnóstico DSM-5 de trastorno leve actual por consumo de cannabis y/o trastorno moderado o grave por consumo de una sustancia distinta del alcohol o la nicotina.","language":7,"languageDescription":"Spanish"}]},{"id":1489866,"number":8,"principalExclusionCriteria":"Significant laboratory abnormalities, including significantly impaired liver function, serious abnormalities of complete blood count or metabolic panel.","principalExclusionCriteriaTranslations":[{"id":10725485,"uuid":"5c11c90a-8851-4518-a990-912f1c9347e0","attributeTranslation":"Anomalías de laboratorio significativas, incluidas alteraciones significativas de la función hepática, anomalías graves del hemograma completo o del panel metabólico.","language":7,"languageDescription":"Spanish"}]},{"id":1489867,"number":9,"principalExclusionCriteria":"Active legal problems likely to result in incarceration within 12 weeks of treatment initiation.","principalExclusionCriteriaTranslations":[{"id":10725486,"uuid":"218a88cf-34e8-4159-b87f-fb748ace57bf","attributeTranslation":"Problemas legales activos que puedan dar lugar a encarcelamiento en las 12 semanas siguientes al inicio del tratamiento.","language":7,"languageDescription":"Spanish"}]}]},"endPoint":{"primaryEndPoints":[{"id":1019989,"number":1,"endPoint":"To evaluate CBD efficacy on alcohol dependance","isPrimary":true,"endPointTranslations":[{"id":10725468,"uuid":"08e47d40-05ff-477e-bc7b-d4f7ec6d90e4","attributeTranslation":"Evaluar la eficacia del CBD en la dependencia del alcohol","language":7,"languageDescription":"Spanish"}]},{"id":1019990,"number":2,"endPoint":"To evaluate psychological symptoms involved in alcohol consumptions","isPrimary":true,"endPointTranslations":[{"id":10725469,"uuid":"c38dcc25-655d-4859-89a7-d14a41ce9c9b","attributeTranslation":"Evaluar sintomas psicologicos en alcoholismo","language":7,"languageDescription":"Spanish"}]},{"id":1019991,"number":3,"endPoint":"To evaluate endocannabinoid system","isPrimary":true,"endPointTranslations":[{"id":10725470,"uuid":"8ba1ddf7-8d1c-4c94-918e-54bac580a0cc","attributeTranslation":"Evaluar el sistema endocanabinoide","language":7,"languageDescription":"Spanish"}]},{"id":1019992,"number":4,"endPoint":"To evaluate CBD tolerability and safety in alcohol dependents","isPrimary":true,"endPointTranslations":[{"id":10725471,"uuid":"730ba3fd-0ef3-49c3-a852-39468d5e4f1a","attributeTranslation":"Evaluar la seguridad y tolerabilidad de CBD en el tratamiento del alcoholismo","language":7,"languageDescription":"Spanish"}]}],"secondaryEndPoints":[]},"trialDuration":{"estimatedEndDate":"2028-10-01","estimatedRecruitmentStartDate":"2026-05-04"},"sourceOfMonetarySupport":[{"id":94336,"organisationName":"Foundation Hospital 12 de Octubre"}],"populationOfTrialSubjects":{"ageRanges":[{"id":353817,"ageRangeCategoryCode":"3","ageRangeCategory":"3"}],"ageRangeSecondaryIds":[],"clinicalTrialGroups":[{"code":"2","name":"Patients"}],"isFemaleSubjects":true,"isMaleSubjects":true,"isVulnerablePopulationSelected":true},"individualParticipantData":{"planToShareIPD":"3"}},"protocolInformation":{"studyDesign":{"periodDetails":[]}},"scientificAdviceAndPip":{"scientificAdvices":[],"paediatricInvestigationPlan":[]},"associatedClinicalTrials":[{"id":33753,"ctNumber":"2023-504439-42-00","sponsorName":"Hospital Universitario 12 De Octubre","fullTitle":"Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)","sponsorAgreementOption":"NON_APPLICABLE","sponsorAgreementOptionName":"NON_APPLICABLE","parentClinicalTrialId":4728,"hasDocument":false,"associatedCtDocs":[]},{"id":33755,"ctNumber":"2023-504439-42-02","sponsorName":"Hospital Universitario 12 De Octubre","fullTitle":"Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)","sponsorAgreementOption":"NON_APPLICABLE","sponsorAgreementOptionName":"NON_APPLICABLE","parentClinicalTrialId":26673,"hasDocument":false,"associatedCtDocs":[]},{"id":33754,"ctNumber":"2023-504439-42-01","sponsorName":"Hospital Universitario 12 De Octubre","fullTitle":"Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)","sponsorAgreementOption":"NON_APPLICABLE","sponsorAgreementOptionName":"NON_APPLICABLE","parentClinicalTrialId":24253,"hasDocument":false,"associatedCtDocs":[]}],"references":[],"pubmedCode":[],"pubmedUrl":[]},"assessmentOutcome":"acceptable_conditions","assessmentOutcomeDate":"2026-06-02","conclusionDate":"2026-06-02","therapeuticAreas":[{"code":"34","name":"Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04]"}],"medicalConditions":[{"id":134357,"medicalCondition":"alcohol dependence","isConditionRareDisease":false}],"sponsors":[{"id":146150,"primary":true,"publicContacts":[{"id":431154,"type":"Public","functionalName":"Gabriel Rubio Valladolid","functionalEmailAddress":"gabriel.rubio@salud.madrid.org","telephone":"+34917790887","organisation":{"id":100743,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Universitario 12 De Octubre","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100028548","organisationLocationStatus":"Active"}}],"scientificContacts":[{"id":431155,"type":"Scientific","functionalName":"Gabriel Rubio Valladolid","functionalEmailAddress":"gabriel.rubio@salud.madrid.org","telephone":"+34917790887","organisation":{"id":100743,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Universitario 12 De Octubre","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100028548","organisationLocationStatus":"Active"}}],"thirdParties":[{"id":659954,"organisationAddress":{"id":541621,"organisation":{"id":574234,"type":"Pharmaceutical company","typeCode":"10","name":"Start From Scratch S.L.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100051140","organisationLocationStatus":"Active"},"address":{"addressId":582698,"oneLine":"Calle De Fernan Gonzalez 28 4 0 F","addressLine1":"Calle De Fernan Gonzalez 28 4 0 F","addressLine2":"","addressLine3":"","addressLine4":"","city":"Madrid","postcode":"28009","country":2027,"countryName":"Spain"},"phone":"+34627513359","email":"jarenas@sfscro.com","isBusinessKeyValidated":true,"businessKey":"ORG-100051140"},"sponsorDuties":[{"id":1024619,"code":"1"},{"id":1024620,"code":"10"},{"id":1024621,"code":"11"},{"id":1024622,"code":"12"},{"id":1024623,"code":"14"},{"id":1024624,"code":"5"},{"id":1024625,"code":"6"},{"id":1024626,"code":"7"},{"id":1024627,"code":"8"}],"phoneNumber":"+34627513359","email":"jarenas@sfscro.com"}],"organisation":{"id":100743,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Universitario 12 De Octubre","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100028548","organisationLocationStatus":"Active"},"addresses":[{"id":97964,"organisation":{"id":100743,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Universitario 12 De Octubre","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100028548","organisationLocationStatus":"Active"},"address":{"addressId":102761,"oneLine":"Bloque D, Avenida De Cordoba S/n","addressLine1":"Bloque D","addressLine2":"Avenida De Cordoba S/n","addressLine3":"","addressLine4":"","city":"Madrid","postcode":"28041","country":2027,"countryName":"Spain"},"isBusinessKeyValidated":true,"businessKey":"LOC-100045672"}],"isCommercial":false,"commercial":"Non-Commercial"}],"trialCategoryCode":"2","trialCategoryJustificationComment":"Phase II trial","partOneTherapeuticAreas":[{"id":1153950,"therapeuticArea":{"code":"34","name":"Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04]"}}],"productRoleGroupInfos":[{"id":398889,"comments":"Placebo to cannabidiol","productRoleCode":"3","productRoleName":"Placebo","products":[{"id":535251,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPharmForm":"N/A","euMpNumber":"N/A","marketingAuthNumber":"N/A","prodName":"Placebo to cannabidiol","pharmForm":"N/A","activeSubstanceName":"N/A","euSubstNumber":"N/A","productOtherName":"N/A","authorisationCountryCode":"IS","nameOrg":"N/A","sponsorSubstanceCode":"N/A","atcCode":"N/A","atcName":"N/A","atcTermLevel":"N/A","activeSubstanceOtherDescriptiveName":"N/A"},"isPaediatricFormulation":false,"mpRoleInTrial":"3","timeUnitCode":"2","evCode":"N/A","devices":[],"characteristics":[],"routes":[],"allSubstancesChemicals":false,"productName":"Placebo to cannabidiol","jsonActiveSubstanceNames":"n/a","pharmaceuticalFormDisplay":"N/A"}]},{"id":398890,"comments":"Cannabidiol","productRoleCode":"1","productRoleName":"Test","products":[{"id":535252,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11344601","productPharmForm":"ORAL SOLUTION","euMpNumber":"PRD11344601","prodAuthStatus":1,"prodName":"Cannabidiol","pharmForm":"ORAL SOLUTION","sponsorProductCode":" Cannabidiol","activeSubstanceName":"CANNABINOL","euSubstNumber":"SUB06074MIG","nameOrg":"START FROM SCRATCH S.L.","productSubstances":[{"productPk":"11344601","substancePk":"331883","nameOrg":"START FROM SCRATCH S.L.","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"CANNABINOL","substanceEvCode":"SUB06074MIG"}],"atcCode":"N03AX24","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"600","doseUomTotal":"mg milligram(s)","maxTotalDoseAmount":"33600","maxTreatmentPeriod":8,"timeUnitCode":"2","evCode":"PRD11344601","sponsorProductCodeEdit":" Cannabidiol","devices":[],"characteristics":["2","1"],"routes":["ORAL USE"],"allSubstancesChemicals":true,"productName":"Cannabidiol","jsonActiveSubstanceNames":"cannabinol","pharmaceuticalFormDisplay":"ORAL SOLUTION"}]}],"isLowIntervention":false},"authorizedPartsII":[{"id":288902,"mscId":57566,"mscInfo":{"id":57566,"clinicalTrialId":27560,"countryOrganisationId":2027,"reportingStatusCode":"Authorised","fromDate":"2026-03-13","toDate":"2026-03-13","isProposedRms":true,"countryName":"Spain","organisationInfo":{},"firstDecisionDate":"2026-06-08","trialStatus":"Authorised","trialPeriod":[],"trialRecruitmentPeriod":[],"hasRecruitmentStarted":false,"activeTrialPeriod":{},"activeTrialRecruitmentPeriod":{},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":322585,"mscId":57566,"trialStatus":"Under evaluation","trialStatusDate":"2026-03-10T18:56:05.026"},{"id":413308,"mscId":57566,"trialStatus":"Authorised","trialStatusDate":"2026-06-08T09:27:46.487"}],"applicationTypeMsc":"1","mscName":"Spain","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-04-30","decision":"authorized_conditions","decisionDate":"2026-06-08"},"decisionDate":"2026-06-08","recruitmentSubjectCount":118,"trialSites":[{"id":1990114,"organisationAddressInfo":{"id":412040,"organisation":{"id":443897,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Universitario 12 De Octubre","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100028548","organisationLocationStatus":"Active"},"address":{"addressId":440655,"oneLine":"Bloque D, Avenida De Cordoba Sn","addressLine1":"Bloque D","addressLine2":"Avenida De Cordoba Sn","addressLine3":"","addressLine4":"","city":"Madrid","postcode":"28041","country":2027,"countryName":"Spain"},"phone":"+34917790887","email":"gabriel.rubio@salud.madrid.org","isBusinessKeyValidated":true,"businessKey":"ORG-100028548"},"personInfo":{"id":2210395,"firstName":"Gabriel","lastName":"Rubio Valladolid","telephone":"+34917790887","email":"gabriel.rubio@salud.madrid.org","title":"1"},"departmentName":"Psiquiatria"}],"applicationStatusCode":"Authorised"}],"applicationInfo":[{"id":76721,"type":"INITIAL","status":"Authorised","ctNumber":"2023-504439-42-03","trialStatus":"Authorised","submissionDate":"2026-03-10","partI":{"assessmentOutcome":"acceptable_conditions","assessmentOutcomeDate":"2026-06-02"},"partIIInfo":[{"id":288902,"mscId":57566,"mscInfo":{"id":57566,"mscName":"Spain","countryOrganisationId":2027,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-04-30","decision":"authorized_conditions","decisionDate":"2026-06-08","reportingStatusCode":"Authorised","countryName":"Spain","trialStatus":"Authorised","firstDecisionDate":"2026-06-08"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-06-08","ctMSCsByApplication":[{"id":57566,"mscName":"Spain","reportingStatusCode":"Authorised"}],"businessKey":"IN-3","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":127307,"applicationId":76721,"mscId":57566,"mscName":"Spain","decisionDate":"2026-06-08T09:27:46.715","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":288902,"part1Id":128814,"applicationType":"INITIAL","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"ca93f913-126d-423e-8969-fe085da940aa","productRoleGroupId":398890}]}],"trialGlobalEnd":[],"memberStatesConcerned":[{"mscName":"Spain","mscId":57566,"firstDecisionDate":"2026-06-08T09:27:46.715","lastDecisionDate":"2026-06-08T09:27:46.715","mscPublicStatusCode":2}],"eudraCt":{"isTransitioned":false}},"events":{"temporaryHaltList":[],"trialEvents":[{"mscId":57566,"mscName":"Spain","events":[]}],"unexpectedEvents":[],"seriousBreaches":[],"urgentSafetyMeasures":[]},"results":{},"documents":[{"title":"D1_protocol 2023-504439-42_V7 08092025","uuid":"b5ee63ff-d75b-4806-a317-39bdc945423f","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"PDF","associatedEntityId":128814,"manualVersion":"8","systemVersion":"2"},{"title":"D1_protocol 2023-504439-42-01_V8 12052026 tracked changes","uuid":"5059b778-35f7-4163-b525-656497842c32","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"PDF","associatedEntityId":128814,"manualVersion":"8","systemVersion":"1"},{"title":"D1_protocol summary 2023-504439-42_V7 08092025","uuid":"dc2e6aaa-5f2f-432c-8771-8489c02a4c14","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","fileType":"PDF","associatedEntityId":128814,"manualVersion":"8","systemVersion":"2"},{"title":"D1_protocol summary 2023-504439-42-01_V8 12052026 tracked changes","uuid":"52571d24-19bb-4443-97c5-f230c2f159ba","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","fileType":"PDF","associatedEntityId":128814,"manualVersion":"8","systemVersion":"1"},{"title":"Cannabidiol USDMF-AP-040825_0325","uuid":"ca93f913-126d-423e-8969-fe085da940aa","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","fileType":"PDF","associatedEntityId":398890,"manualVersion":"1","systemVersion":"1"},{"title":"K1_recruitment arrangements for publication","uuid":"1d304906-ce8f-4c5b-948f-a500bdb8d81e","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","fileType":"PDF","associatedEntityId":288902,"manualVersion":"1","systemVersion":"1"},{"title":"L1_SIS and ICF V1 21112024 pregnancy","uuid":"56d61dcf-f53a-4997-8535-a40439b3fbd8","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":288902,"manualVersion":"1","systemVersion":"1"},{"title":"L1 SIS and ICF V5 20250623","uuid":"db67dcf7-3f19-42fa-9f7a-fd94c86ebd7a","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":288902,"manualVersion":"5","systemVersion":"1"}],"trialRegion":"EEA","trialRegionCode":1,"correctiveMeasures":[]}